{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:04:39Z","timestamp":1771538679167,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T00:00:00Z","timestamp":1494201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Ophthalmol Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40135-017-0133-4","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T04:40:11Z","timestamp":1494218411000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy"],"prefix":"10.1007","volume":"5","author":[{"given":"Brian E.","family":"Goldhagen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Goldhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"key":"133_CR1","first-page":"66","volume-title":"Diseases causing exudative and hemorrhagic detachment of the choroid, retina and retinal pigment epithelium. Gass' atlas of macular diseases","author":"A Agarwal","year":"2012","unstructured":"Agarwal A. Diseases causing exudative and hemorrhagic detachment of the choroid, retina and retinal pigment epithelium. Gass' atlas of macular diseases. 5th ed. Edinburgh: Elsevier Saunders; 2012. p. 66\u201391.","edition":"5"},{"issue":"1","key":"133_CR2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology. 2008;115(1):169\u201373.","journal-title":"Ophthalmology"},{"issue":"2","key":"133_CR3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ophtha.2003.09.024","volume":"111","author":"R Haimovici","year":"2004","unstructured":"Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004;111(2):244\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"133_CR4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0002-9394(99)00075-6","volume":"128","author":"MK Tittl","year":"1999","unstructured":"Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63\u20138.","journal-title":"Am J Ophthalmol"},{"key":"133_CR5","first-page":"799","volume":"84","author":"LA Yannuzzi","year":"1986","unstructured":"Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799\u2013845.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"133_CR6","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0161-6420(96)30386-2","volume":"103","author":"RF Spaide","year":"1996","unstructured":"Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103(12):2070\u20139. discussion 2079-2080","journal-title":"Ophthalmology"},{"issue":"2","key":"133_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IAE.0000000000000326","volume":"35","author":"FL Brodie","year":"2015","unstructured":"Brodie FL, Charlson ES, Aleman TS, et al. Obstructive sleep apnea and central serous chorioretinopathy. Retina. 2015;35(2):238\u201343.","journal-title":"Retina"},{"issue":"2","key":"133_CR8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.47102\/annals-acadmedsg.V35N2p77","volume":"35","author":"AC How","year":"2006","unstructured":"How AC, Koh AH. Angiographic characteristics of acute central serous chorioretinopathy in an Asian population. Ann Acad Med Singap. 2006;35(2):77\u20139.","journal-title":"Ann Acad Med Singap"},{"issue":"6","key":"133_CR9","doi-asserted-by":"crossref","first-page":"e66858","DOI":"10.1371\/journal.pone.0066858","volume":"8","author":"DC Tsai","year":"2013","unstructured":"Tsai DC, Chen SJ, Huang CC, et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001\u20132006: a population-based study. PLoS One. 2013;8(6):e66858.","journal-title":"PLoS One"},{"issue":"7","key":"133_CR10","first-page":"553","volume":"95","author":"UR Desai","year":"2003","unstructured":"Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR. Central serous chorioretinopathy in African Americans. J Natl Med Assoc. 2003;95(7):553\u20139.","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"133_CR11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9394(14)73760-2","volume":"120","author":"MR Hee","year":"1995","unstructured":"Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1):65\u201374.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"133_CR12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","volume":"29","author":"Y Imamura","year":"2009","unstructured":"Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29(10):1469\u201373.","journal-title":"Retina"},{"issue":"4","key":"133_CR13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archopht.1974.03900060257001","volume":"91","author":"ML Klein","year":"1974","unstructured":"Klein ML, Van Buskirk EM, Friedman E, Gragoudas E, Chandra S. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol. 1974;91(4):247\u201350.","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"133_CR14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bjo.68.11.815","volume":"68","author":"CM Gilbert","year":"1984","unstructured":"Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68(11):815\u201320.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"133_CR15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00169099","volume":"81","author":"J Castro-Correia","year":"1992","unstructured":"Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol. 1992;81(4):379\u201386.","journal-title":"Doc Ophthalmol"},{"issue":"11","key":"133_CR16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bjo.72.11.829","volume":"72","author":"L Ficker","year":"1988","unstructured":"Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988;72(11):829\u201334.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"133_CR17","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.ophtha.2004.03.025","volume":"111","author":"T Sharma","year":"2004","unstructured":"Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology. 2004;111(9):1708\u201314.","journal-title":"Ophthalmology"},{"issue":"1","key":"133_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00417-015-2989-z","volume":"254","author":"S Shulman","year":"2016","unstructured":"Shulman S, Goldenberg D, Schwartz R, et al. Oral rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(1):15\u201322.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"133_CR19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00417-016-3315-0","volume":"254","author":"O Zavoloka","year":"2016","unstructured":"Zavoloka O, Bezditko P, Lahorzhevska I, Zubkova D, Ilyina Y. Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1737\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"133_CR20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/TCRM.S50407","volume":"9","author":"Y Dang","year":"2013","unstructured":"Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y. The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients. Ther Clin Risk Manag. 2013;9:355\u201360.","journal-title":"Ther Clin Risk Manag"},{"key":"133_CR21","first-page":"99","volume":"17","author":"MB Rahbani-Nobar","year":"2011","unstructured":"Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis. 2011;17:99\u2013103.","journal-title":"Mol Vis"},{"issue":"9","key":"133_CR22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0161-6420(02)01157-0","volume":"109","author":"J Pikkel","year":"2002","unstructured":"Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723\u20135.","journal-title":"Ophthalmology"},{"issue":"1","key":"133_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10792-013-9774-y","volume":"34","author":"C Brandl","year":"2014","unstructured":"Brandl C, Helbig H, Gamulescu MA. Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol. 2014;34(1):7\u201313.","journal-title":"Int Ophthalmol"},{"issue":"6","key":"133_CR24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/eye.2016.53","volume":"30","author":"E Moisseiev","year":"2016","unstructured":"Moisseiev E, Holmes AJ, Moshiri A, Morse LS. Finasteride is effective for the treatment of central serous chorioretinopathy. Eye (Lond). 2016;30(6):850\u20136.","journal-title":"Eye (Lond)."},{"issue":"1","key":"133_CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5507\/bp.2013.015","volume":"159","author":"O Chrapek","year":"2015","unstructured":"Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):120\u20133.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2415-12-20","volume":"12","author":"M Ratanasukon","year":"2012","unstructured":"Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol. 2012;12:20.","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"133_CR27","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1167\/iovs.14-14470","volume":"55","author":"M Sawa","year":"2014","unstructured":"Sawa M, Gomi F, Hara C, Nishida K. Effects of a lutein supplement on the plasma lutein concentration and macular pigment in patients with central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2014;55(8):5238\u201344.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"133_CR28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/eye.2015.104","volume":"29","author":"AL Gramajo","year":"2015","unstructured":"Gramajo AL, Marquez GE, Torres VE, et al. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye (Lond). 2015;29(8):1036\u201345.","journal-title":"Eye (Lond)"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2147\/OPTH.S12583","volume":"4","author":"A Caccavale","year":"2010","unstructured":"Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899\u2013903.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"133_CR30","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, Celerier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"133_CR31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0039-6257(02)00338-7","volume":"47","author":"EA Bouzas","year":"2002","unstructured":"Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431\u201348.","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"133_CR32","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00417-014-2780-6","volume":"252","author":"TR Herold","year":"2014","unstructured":"Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW. Spironolactone in the treatment of central serous chorioretinopathy\u2014a case series. Graefes Arch Clin Exp Ophthalmol. 2014;252(12):1985\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"133_CR33","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","volume":"33","author":"E Bousquet","year":"2013","unstructured":"Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33(10):2096\u2013102.","journal-title":"Retina"},{"issue":"12","key":"133_CR34","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"\u2022 Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35(12):2505\u201315. In a randomized controlled crossover study, patients with chronic CSCR demonstrated improvement in SRF after treatment with spironolactone 50\u00a0mg for a month as compared with placebo","journal-title":"Retina"},{"key":"133_CR35","doi-asserted-by":"crossref","unstructured":"Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study G. Comparison of two mineralcorticosteroid receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2016.","DOI":"10.1007\/s10792-016-0377-2"},{"issue":"4","key":"133_CR36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","volume":"57","author":"JA Delyani","year":"2000","unstructured":"Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000;57(4):1408\u201311.","journal-title":"Kidney Int"},{"issue":"3","key":"133_CR37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3341\/kjo.2010.24.3.155","volume":"24","author":"JW Lim","year":"2010","unstructured":"Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24(3):155\u20138.","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"133_CR38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000345495","volume":"229","author":"M Kim","year":"2013","unstructured":"Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229(3):152\u20137.","journal-title":"Ophthalmologica"},{"issue":"1","key":"133_CR39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/2008-322X.180700","volume":"11","author":"C Unlu","year":"2016","unstructured":"Unlu C, Erdogan G, Aydogan T, et al. Intravitreal bevacizumab for treatment of central serous chorioretinopathy. J Ophthalmic Vis Res. 2016;11(1):61\u20135.","journal-title":"J Ophthalmic Vis Res"},{"key":"133_CR40","doi-asserted-by":"crossref","unstructured":"Tekin K, Sekeroglu MA, Cankaya AB, Teke MY, Doguizi S, Yilmazbas P. Intravitreal bevacizumab and Ranibizumab in the treatment of acute central serous chorioretihopathy: a single center retrospective study. Semin Ophthalmol. 2016:1\u20136.","DOI":"10.1080\/08820538.2016.1228985"},{"issue":"6","key":"133_CR41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/bjophthalmol-2014-306018","volume":"99","author":"JD Pitcher 3rd","year":"2015","unstructured":"Pitcher 3rd JD, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848\u201352.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"133_CR42","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1097\/IAE.0000000000000655","volume":"35","author":"J Chhablani","year":"2015","unstructured":"Chhablani J, Kozak I, Pichi F, et al. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina. 2015;35(12):2489\u201397.","journal-title":"Retina"},{"issue":"7","key":"133_CR43","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"12","key":"133_CR44","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","volume":"87","author":"WM Chan","year":"2003","unstructured":"Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"133_CR45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/02713683.2014.1002047","volume":"41","author":"MR Munk","year":"2016","unstructured":"Munk MR, Shah R, Pappas F, et al. Multimodal imaging and choroidal volumetric changes after half-fluence PDT in central serous chorioretinopathy. Curr Eye Res. 2016;41(1):97\u2013106.","journal-title":"Curr Eye Res"},{"issue":"5","key":"133_CR46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s004170050092","volume":"236","author":"U Schmidt-Erfurth","year":"1998","unstructured":"Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol. 1998;236(5):365\u201374.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"133_CR47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ajo.2009.08.026","volume":"149","author":"M Reibaldi","year":"2010","unstructured":"Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307\u201315. e302","journal-title":"Am J Ophthalmol"},{"key":"133_CR48","doi-asserted-by":"crossref","unstructured":"Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of Verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina. 2016.","DOI":"10.1097\/IAE.0000000000001138"},{"key":"133_CR49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ajo.2016.04.001","volume":"167","author":"HY Liu","year":"2016","unstructured":"Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT. Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol. 2016;167:57\u201364.","journal-title":"Am J Ophthalmol"},{"key":"133_CR50","doi-asserted-by":"crossref","unstructured":"\u2022 Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073\u20138. In a large retrospective case series, PDT was demonstrated to be safe and is associated with both resolution of SRF and improvement of vision in patient with chronic CSCR","DOI":"10.1016\/j.ophtha.2013.11.040"},{"key":"133_CR51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","volume":"170","author":"FH Lai","year":"2016","unstructured":"Lai FH, Ng DS, Bakthavatsalam M, et al. A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2016;170:91\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"133_CR52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","volume":"22","author":"RH Loo","year":"2002","unstructured":"Loo RH, Scott IU, Flynn Jr HW, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22(1):19\u201324.","journal-title":"Retina"},{"issue":"6","key":"133_CR53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/aos.13059","volume":"94","author":"MB Breukink","year":"2016","unstructured":"Breukink MB, Mohabati D, van Dijk EH, et al. Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study. Acta Ophthalmol. 2016;94(6):565\u201372.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"133_CR54","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1167\/iovs.15-18981","volume":"57","author":"D Lavinsky","year":"2016","unstructured":"\u2022 Lavinsky D, Wang J, Huie P, et al. Nondamaging retinal laser therapy: rationale and applications to the macula. Invest Ophthalmol Vis Sci. 2016;57(6):2488\u2013500. In a prospective series evaluating nondamaging (subthreshold) retinal laser therapy using the PASCAL Endpoint Management system in chronic CSCR, both vision and SRF were seen to improve after treatment. Additionally, in animal model, heat-shock protein upregulation was seen 1\u00a0month after treatment without evidence of retinal tissue damage","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"133_CR55","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/OPTH.S87499","volume":"9","author":"AH Abd Elhamid","year":"2015","unstructured":"Abd Elhamid AH. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin Ophthalmol. 2015;9:2277\u201383.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"133_CR56","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00417-015-2965-7","volume":"253","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim SY. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2129\u201335.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"133_CR57","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3928\/23258160-20150909-08","volume":"46","author":"FT Kretz","year":"2015","unstructured":"\u2022 Kretz FT, Beger I, Koch F, Nowomiejska K, Auffarth GU, Koss MJ. Randomized clinical trial to compare Micropulse photocoagulation versus half-dose Verteporfin photodynamic therapy in the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):837\u201343. In a prospective study comparing subthreshold diode micropulse laser and half-dose PDT to control in patients with chronic CSCR, both micropulse laser and PDT resulted in a decrease of leakage on FA and an improvement of vision","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"133_CR58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/IAE.0000000000000285","volume":"35","author":"KJ Malik","year":"2015","unstructured":"Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity\/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35(3):532\u20136.","journal-title":"Retina"},{"issue":"4","key":"133_CR59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000439600","volume":"234","author":"P Scholz","year":"2015","unstructured":"Scholz P, Ersoy L, Boon CJ, Fauser S. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica. 2015;234(4):189\u201394.","journal-title":"Ophthalmologica"},{"issue":"2","key":"133_CR60","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/eye.2014.315","volume":"29","author":"NK Yadav","year":"2015","unstructured":"Yadav NK, Jayadev C, Mohan A, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye (Lond). 2015;29(2):258\u201364. quiz 265","journal-title":"Eye (Lond)."},{"issue":"2","key":"133_CR61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/aos.12938","volume":"94","author":"MB Breukink","year":"2016","unstructured":"Breukink MB, Mohr JK, Ossewaarde-van Norel A, et al. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Acta Ophthalmol. 2016;94(2):187\u201397.","journal-title":"Acta Ophthalmol"},{"key":"133_CR62","doi-asserted-by":"crossref","first-page":"3513794","DOI":"10.1155\/2016\/3513794","volume":"2016","author":"E Ozmert","year":"2016","unstructured":"Ozmert E, Demirel S, Yanik O, Batioglu F. Low-fluence photodynamic therapy versus subthreshold micropulse yellow wavelength laser in the treatment of chronic central serous chorioretinopathy. J Ophthalmol. 2016;2016:3513794.","journal-title":"J Ophthalmol"},{"issue":"10","key":"133_CR63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/eye.2016.142","volume":"30","author":"P Scholz","year":"2016","unstructured":"Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond). 2016;30(10):1371\u20137.","journal-title":"Eye (Lond)."},{"issue":"2","key":"133_CR64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/IAE.0b013e3182670fa3","volume":"33","author":"M Behnia","year":"2013","unstructured":"Behnia M, Khabazkhoob M, Aliakbari S, Abadi AE, Hashemi H, Pourvahidi P. Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. Retina. 2013;33(2):324\u20138.","journal-title":"Retina"},{"issue":"5","key":"133_CR65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3928\/23258160-20130909-08","volume":"44","author":"L Roisman","year":"2013","unstructured":"Roisman L, Magalhaes FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):465\u201370.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"133_CR66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/IAE.0000000000000340","volume":"35","author":"D Lavinsky","year":"2015","unstructured":"Lavinsky D, Palanker D. Nondamaging photothermal therapy for the retina: initial clinical experience with chronic central serous retinopathy. Retina. 2015;35(2):213\u201322.","journal-title":"Retina"},{"key":"133_CR67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13063-015-0939-z","volume":"16","author":"MB Breukink","year":"2015","unstructured":"Breukink MB, Downes SM, Querques G, et al. Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial. Trials. 2015;16:419.","journal-title":"Trials"},{"issue":"12","key":"133_CR68","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.ophtha.2008.08.026","volume":"115","author":"SN Chen","year":"2008","unstructured":"Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229\u201334.","journal-title":"Ophthalmology"},{"issue":"9","key":"133_CR69","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1097\/IAE.0000000000001005","volume":"36","author":"JK Luttrull","year":"2016","unstructured":"Luttrull JK. Low-intensity\/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina. 2016;36(9):1658\u201363.","journal-title":"Retina"},{"key":"133_CR70","doi-asserted-by":"crossref","unstructured":"Mehta PH, Meyerle C, Sivaprasad S, Boon C, Chhablani J. Preferred practice pattern in central serous chorioretinopathy. Br J Ophthalmol. 2016.","DOI":"10.1136\/bjophthalmol-2016-309247"}],"container-title":["Current Ophthalmology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40135-017-0133-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40135-017-0133-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40135-017-0133-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T23:58:00Z","timestamp":1719187080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40135-017-0133-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s40135-017-0133-4","relation":{},"ISSN":["2167-4868"],"issn-type":[{"value":"2167-4868","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]}}}